|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.2 CNY | -3.77% |
|
-9.98% | -23.21% |
| May. 06 | Biocytogen Enters into Evaluation and Potential Licensing Agreement with Biocopy for TCR-mimic Antibodies | CI |
| Apr. 26 | Biocytogen Pharmaceuticals' Loss Narrows in 2023 | MT |
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was CNY 326.84 million compared to CNY 229.13 million a year ago. Net loss was CNY 189.81 million compared to CNY 272.39 million a year ago.
Basic loss per share from continuing operations was CNY 0.48 compared to CNY 0.73 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -23.21% | 471M | |
| +33.37% | 50.85B | |
| +1.55% | 42.82B | |
| +49.28% | 42.03B | |
| -4.22% | 29.55B | |
| +11.57% | 26.11B | |
| -21.00% | 19.13B | |
| +7.36% | 13.05B | |
| +28.30% | 12.16B | |
| +23.80% | 12.08B |
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. 
